Dr Chiswell has over 30 years' experience in the biotechnology industry having co-founded Cambridge Antibody Technology (CAT) in 1990, serving as CEO from 1996 to 2002. He was Chair of Kymab from 2012 and CEO from 2015 until early 2019, when he became a Scientific advisor.
CAT listed on the London Stock exchange in April 1997 and Nasdaq in June 2001, and was subsequently sold to AstraZenca where it forms an important part of their biopharmaceutical franchise. Since leaving CAT in 2002, he has focused on the development of early-stage biotechnology companies, having previously served as a director of Arakis, non-executive chairman of Sosei, Arrow Therapeutics and Daniolabs, and as CEO of Nabriva Therapeutics (2009 to 2012). Dr Chiswell currently serves as chairman of Albireo Pharma and is a director of Nabriva Therapeutics. He is a past chairman of the UK BioIndustry Association (BIA) and in 2006 he was awarded the Most Excellent Order of the British Empire (OBE) by Her Majesty the Queen for services to the biotechnology industry.